XORTX Therapeutics Inc. (XRTX)
NASDAQ: XRTX · Real-Time Price · USD
0.4100
+0.0090 (2.24%)
At close: Mar 16, 2026, 4:00 PM EDT
0.4169
+0.0069 (1.68%)
After-hours: Mar 16, 2026, 6:03 PM EDT

XORTX Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
2.573.823.493.472.22
Depreciation & Amortization Expenses
0.110.120.140.060.01
Research & Development
0.570.182.426.760.68
Other Operating Expenses
-0----
Total Operating Expenses
3.254.126.0510.292.91
Operating Income
-3.26-4.12-6.05-10.29-2.91
Interest Income
0.040.120.250.1-
Interest Expense
-----0
Other Non-Operating Income (Expense)
0.560.683.632.471.34
Total Non-Operating Income (Expense)
0.60.83.892.571.33
Pretax Income
-2.66-3.31-2.16-7.72-1.58
Net Income
-2.66-3.31-2.16-7.72-1.58
Net Income to Common
-2.66-3.31-2.16-7.72-1.58
Shares Outstanding (Basic)
53211
Shares Outstanding (Diluted)
53211
Shares Change (YoY)
64.48%45.25%33.91%35.25%47.77%
EPS (Basic)
-0.56-1.15-1.09-5.22-1.44
EPS (Diluted)
-0.56-1.15-1.09-5.22-1.44
Free Cash Flow
-2.77-3.68-6.59-8.19-4.8
Free Cash Flow Per Share
-0.58-1.28-3.32-5.53-4.39
EBITDA
-3.15-4-5.91-10.23-2.9
EBIT
-3.26-4.12-6.05-10.29-2.91
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q